İsmail BASMACI, Serdar ÇELİK, Ertuğrul ŞEFİK, M. Erhan AYDIN, İBRAHİM HALİL BOZKURT, BÜLENT GÜNLÜSOY, TANSU DEĞİRMENCİ

RENAL HÜCRELİ KANSERDE AST/ALT VE ALBUMİN/GLOBÜLİN ORANININ PROGNOSTİK BELİRTEÇ OLARAK DEĞERLENDİRİLMESİ

Giriş: Renal Hücreli Kanserde (RHK) prognostik belirteç olarak Aspartat aminotransferaz(AST)/Alanin aminotransferaz (ALT) ve Albumin/Globülin oranının (AGO) etkinliği araştırmak. Gereç ve Yöntem: Ocak 2012-Eylül 2017 tarihleri arasında böbrek tümörü nedeniyle cerrahi tedavi uygulanan ve patolojisi RHK olan 125 hastanın preoperatif AST/ALT ve AGO değerlendirildi. Hastalar ilk önce tanı anında metastatik olan ve metastaz saptanmayan olarak iki gruba ayrıldı. Ardından hastaların patolojik T evresine göre iki gruba ayrıldı. İlk grupta T1 ve T2 evreli lokalize hastalar, diğer grupta T3 ve T4 evreli invaziv hastalar değerlendirilerek veriler bu iki grup arasında karşılaştırılarak incelendi. Bulgular: AST/ALT oranı metastazı olmayan grupta 1,2±0,6 iken, metastazı olan grupta 0,8±0,2’di (p=0,021). Yapılan çok değişkenli analizde gruplar arası anlamlı fark gözlenmemiştir AGO açısından ise her iki grup arasında istatistiksel anlamlı fark saptanmadı (p=0,639). Sonuç: AST/ALT oranı ile AGO’nın lokal invaziv hastalık ve tanı anında metastaz ile ilişkili olmadığı gösterildi.

PDF

___

Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001; 40(3): 252-5.
Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51(2): 203-5.
Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: Study of 1092 patients (1982-1997). Urology 2000; 56(1): 58-62.
Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clın.Oncology 2006; 24(19): 3101-6.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6): 1471–4.
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6(7):655–63.
Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol 2010; 28(3): 319-27.
Azab BN, Bhatt VR, Vonfrolio S, Bachir R, Rubinshteyn V, Alkaied H, et al. Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 2013; 206(5): 764-70.
Azab B, Kedia S, Shah N, Vonfrolio S, Lu W, Naboush A, et al. The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis 2013; 28(12): 1629-36.
Brierley, JD. TNM classification of malignant tumors. UICC International Union Against Cancer. 8th ed. Wiley-Blackwell, 2017p. 199.
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6(7): 655–63.
Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104(7): 1362 -71.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168(6): 2395-400.
Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19(6): 1649-57.
Karakiewicz PI, Briganti A, Chun FK. Multiinstitutional validation of a new renal cancer specific survival nomogram. J Clin Oncol 2007; 25: 1316-22.
Poon RT, Fan ST, Lo C. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B related cirrhosis. J Clin Oncol 2000; 18(5): 1094-111.
Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alanine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther 2008;4: 21-5.
Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134(5):703-7.
Sudarshan S1, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, et al. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol 2013; 63(2):244-51.
Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R et al. The preoperative AST/ALT (De ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol 2015; 194(1): 30– 5.
McMillan DC, Watson WS, O ‫׳‬Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001; 39(2): 210-3.